ArticleHuman vaccines & immunotherapeutics2021
Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.Journal of gynecologic oncology · 2022Pooled it
- Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.Human vaccines & immunotherapeutics · 2026Article
- Economic evaluation of 22 HPV vaccination strategies to minimize the risk of penile, anal, and oropharyngeal cancers in Chinese males: A Markov model analysis.Human vaccines & immunotherapeutics · 2026Article
- Age of acquisition of disease-causal human papillomavirus infection to high-grade cervical intraepithelial neoplasia (CIN2+) in England.BMC infectious diseases · 2026Article
- Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia.Journal of health economics and outcomes research · 2026Article
- Expanding HPV prevention across the life course: evidence on vaccine effectiveness in adults.Frontiers in public health · 2026Review
- The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study.BMC public health · 2025Article
- A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.Human vaccines & immunotherapeutics · 2025Article
- Cost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany.Infection · 2025Article
- Article
- Qualitative assessment of sex-stratified human papillomavirus transmission dynamics in South Korea.BMC public health · 2025Article
- Improving HPV Vaccine Coverage in Tennessee: Addressing Barriers and Expanding Access for Mid-Adults.Pathogens (Basel, Switzerland) · 2025Review
- Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study.BMC public health · 2025Article
- Article
- Strategies to accelerate cervical cancer elimination in Greece: a modeling study.Frontiers in oncology · 2025Article
- Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay.Frontiers in public health · 2025Article
- Observational
- Article
- Structured Literature Review to Identify Human Papillomavirus's Natural History Parameters for Dynamic Population Models of Vaccine Impacts.Infectious diseases and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27-45 years, compared with catch-up through age 26 years and 21 years for females and males, respectively (status quo; pre-June-2019 recommendations). This study assessed the public health impact and cost-effectiveness of expanded catch-up vaccination through age 45 years (expanded catch-up) compared with status quo. We used an HPV dynamic transmission infection and disease model to assess disease outcomes and incremental cost-effectiveness ratio (ICER) of expanded catch-up compared with status quo. Costs (2018 USD), calculated from a healthcare sector perspective, and quality-adjusted life years (QALY) were discounted at 3% annually. Historical vaccination coverage was estimated using NIS-TEEN survey data (NHANES data for sensitivity analysis). Alternative scenario analyses included restricting upper age of expanded catch-up through 26 years (June-2019 ACIP recommendation), 29 years, and further 5-year increments. Our results show expanded catch-up vaccination would prevent additional 37,856 cancers, 314,468 cervical intraepithelial neoplasia-2/3s, 1,743,461 genital warts, and 10,698 deaths compared with status quo over 100 years at cost of $141,000/QALY. With NHANES coverage, the ICER was $96,000/QALY. The June-2019 ACIP recommendation also provided public health benefits with an ICER of $117,000/QALY, compared with status quo. The ICER for expanded vaccination through age 34 years was $107,000/QALY. Expanding catch-up vaccination program through age 45 years-old in the US is expected to provide public health benefits, and cost-effectiveness improves with expanding catch-up through age 34.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.